GSTM1 and anemia (phenotype): The CREATE [217] trial assessed the effect of epoetin beta (ESA) administration on CV events in 603 patients with Stage 3 or 4 CKD and mild-to-moderate anaemia (Hb 11.0–12.5 g/dL).